[go: up one dir, main page]

NO20090797L - Farmasoytiske blandinger omfattende kandesartan cileksetil - Google Patents

Farmasoytiske blandinger omfattende kandesartan cileksetil

Info

Publication number
NO20090797L
NO20090797L NO20090797A NO20090797A NO20090797L NO 20090797 L NO20090797 L NO 20090797L NO 20090797 A NO20090797 A NO 20090797A NO 20090797 A NO20090797 A NO 20090797A NO 20090797 L NO20090797 L NO 20090797L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
candesartan cilexetil
candesartan
cilexetil
composition
Prior art date
Application number
NO20090797A
Other languages
English (en)
Norwegian (no)
Inventor
Bertil Abrahamsson
Jonas Odman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090797L publication Critical patent/NO20090797L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20090797A 2006-09-05 2009-02-20 Farmasoytiske blandinger omfattende kandesartan cileksetil NO20090797L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84243206P 2006-09-05 2006-09-05
PCT/SE2007/000771 WO2008030161A1 (fr) 2006-09-05 2007-09-04 composition pharmaceutique comprenant DU CANDESARTAN CILEXETIL

Publications (1)

Publication Number Publication Date
NO20090797L true NO20090797L (no) 2009-03-19

Family

ID=39157499

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090797A NO20090797L (no) 2006-09-05 2009-02-20 Farmasoytiske blandinger omfattende kandesartan cileksetil

Country Status (12)

Country Link
US (1) US20080058399A1 (fr)
EP (1) EP2063888A4 (fr)
JP (1) JP2010502698A (fr)
KR (1) KR20090049089A (fr)
CN (1) CN101528224A (fr)
AU (1) AU2007293727A1 (fr)
BR (1) BRPI0716445A2 (fr)
CA (1) CA2662040A1 (fr)
IL (1) IL197093A0 (fr)
MX (1) MX2009002425A (fr)
NO (1) NO20090797L (fr)
WO (1) WO2008030161A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079198A2 (fr) * 2005-12-29 2007-07-12 Teva Pharmaceutical Industries Ltd. Formulations de metaxalone et procedes de preparation
RU2009141539A (ru) * 2007-04-25 2011-05-27 Тева Фармасьютикал Индастриес Лтд. (Il) Комплекс фармацевтического наполнителя
CA2705625A1 (fr) * 2007-08-01 2009-02-05 Teva Pharmaceutical Industries Ltd. Formulations ameliorees de candesartan
DE102007052070A1 (de) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
EP2106789A1 (fr) * 2008-03-31 2009-10-07 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique comprenant du candesartan
CN101862325B (zh) * 2009-04-20 2013-12-04 北京德众万全药物技术开发有限公司 一种含有坎地沙坦酯的药物组合物
HUP0900376A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
HUP0900384A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
CZ302789B6 (cs) * 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
WO2011109579A1 (fr) * 2010-03-04 2011-09-09 Theravance, Inc. Acide alcoxyimidazol-1-ylméthylbiphénylcarboxylique cristallin et ses procédés de préparation
JP2012051829A (ja) * 2010-08-31 2012-03-15 Taiyo Yakuhin Kogyo Kk 安定なアンジオテンシｉｉ受容体拮抗作用を示す薬物製剤の設計
JP5756651B2 (ja) * 2011-02-24 2015-07-29 エルメッド エーザイ株式会社 カンデサルタンシレキセチルを安定化した組成物及びその製造方法
JP2013067574A (ja) * 2011-09-21 2013-04-18 Teva Pharma Japan Inc 安定化された医薬組成物
WO2014010008A1 (fr) * 2012-07-09 2014-01-16 東洋カプセル株式会社 Composition de candésartan cilexétil destinée à être remplie dans une capsule
CN102885810B (zh) * 2012-10-30 2015-08-05 台州职业技术学院 一种坎地沙坦酯双释胶囊及其制备方法
JP6379043B2 (ja) 2013-01-30 2018-08-22 沢井製薬株式会社 カンデサルタンシレキセチル含有医薬組成物
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198591C (zh) * 1998-07-20 2005-04-27 史密丝克莱恩比彻姆公司 在口服固体剂型中包含依普沙坦的生物利用度提高的制剂
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
WO2005079751A2 (fr) * 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales de candesartan cilexetil
WO2005070398A2 (fr) * 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Compositions pharmaceutiques de candesartan cilexetil stabilisees par des co-solvants
CA2555294A1 (fr) * 2004-02-11 2005-08-25 Marina Yu Etinger Polymorphes de candesartan cilexetil
WO2005123721A2 (fr) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Formes amorphes et polymorphes de candesartan cilexetil
EP1655298A1 (fr) * 2004-11-03 2006-05-10 LEK Pharmaceuticals d.d. Formes polymorphes du candesartan cilexetil
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
US20060111417A1 (en) * 2004-11-23 2006-05-25 Purandhar Koilkonda Amorphous telmisartan
JP2008526855A (ja) * 2005-01-06 2008-07-24 エラン ファーマ インターナショナル リミテッド ナノ粒子のカンデサルタン製剤
WO2006113631A2 (fr) * 2005-04-18 2006-10-26 Rubicon Research Pvt. Ltd. Compositions ameliorees biologiquement

Also Published As

Publication number Publication date
US20080058399A1 (en) 2008-03-06
JP2010502698A (ja) 2010-01-28
BRPI0716445A2 (pt) 2013-09-17
MX2009002425A (es) 2009-03-20
CA2662040A1 (fr) 2008-03-13
IL197093A0 (en) 2009-11-18
EP2063888A1 (fr) 2009-06-03
AU2007293727A1 (en) 2008-03-13
EP2063888A4 (fr) 2009-11-04
WO2008030161A1 (fr) 2008-03-13
KR20090049089A (ko) 2009-05-15
CN101528224A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
NO20090797L (no) Farmasoytiske blandinger omfattende kandesartan cileksetil
NO20091395L (no) Nye tiofenderivater
NO20083462L (no) Nye tiofenderivater som S1P1/EDG1-reseptoragonister
WO2008006528A3 (fr) Nouvelles compositions pharmaceutiques comprenant du lévétiracétam
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
NO20082793L (no) Nye tiofenderivater
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
WO2009156462A3 (fr) Composés organiques
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
WO2010012442A8 (fr) Dérivé de benzènedicarboxamide insecticide
EP2078731A4 (fr) Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
BRPI0921063B8 (pt) composto, e, composição agonística para receptor de melanocortina
NI201000172A (es) Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la hospitalización cardiovascular o de la mortalidad.
BR112012024428A2 (pt) composição farmacêutica de dissolução rápida
CL2007001919A1 (es) Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos.
WO2007090661A3 (fr) Combinaison de substances actives
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
WO2008154234A3 (fr) Formulation à libération prolongée de névirapine
CY1109865T1 (el) Συνθεσεις βαλσαρτανης
WO2009038412A3 (fr) Composés inhibiteurs de la béta-sécrétase
CL2007002812A1 (es) Compuestos derivados de quinolina; composicion farmaceutica, utiles para inhibir el vih.
ECSP10010683A (es) Una formulacion farmacéutica sólida
WO2011014003A3 (fr) Dérivés de (+)-3-(+)-3-hydroxymorphinan utilisés comme neuroprotecteurs

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application